To include your compound in the COVID-19 Resource Center, submit it here.

Tesaro combo leads to partial responses in NSCLC patients

Tesaro Inc. (NASDAQ:TSRO) reported data from the open-label Phase I AMBER trial showing that a combination of

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE